Tipranavir je organsko jedinjenje, koje sadrži 31 atom ugljenika i ima molekulsku masu od 602,664 Da.[1][2][3][4][5][6]

Tipranavir
Tipranavir.svg
Klinički podaci
Prodajno imeAptivus, Aptivus (Boehringer Ingelheim)
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije5-6 h
Identifikatori
CAS broj174484-41-4 ДаY
ATC kodJ05AE09 (WHO)
PubChemCID 65027
DrugBankDB00932 ДаY
ChemSpider58539 ДаY
ChEMBLCHEMBL183041 ДаY
Hemijski podaci
FormulaC31H33F3N2O5S
Molarna masa602,664

OsobineУреди

Osobina Vrednost
Broj akceptora vodonika 6
Broj donora vodonika 2
Broj rotacionih veza 12
Particioni koeficijent[7] (ALogP) 7,4
Rastvorljivost[8] (logS, log(mol/L)) -9,6
Polarna površina[9] (PSA, Å2) 114,0

ReferenceУреди

  1. ^ Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005 Oct;68(1):27-35. PMID 16122817
  2. ^ Tipranavir: PNU 140690, tipranivir. Drugs R D. 2006;7(1):55-62. PMID 16620137
  3. ^ Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. PMID 17712762
  4. ^ Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. PMID 18158073
  5. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  6. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  7. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  8. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  9. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

LiteraturaУреди

Spoljašnje vezeУреди

 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).